-
-
-
-
-
-
-
Mirum and Incyte to present zilurgisertib study results at ENDO 2026
-
-
-
-
-
-
-
Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Mirum Pharmaceuticals (MIRM) Announces Extension of PDUFA Date for LIVMARLI to March 13, 2024
-
-
-
-
-
-
-
Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan
-
-
-
-
-
-
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Mirum Pharmaceuticals Presents Analyses From Its Rare Liver Disease Programs at the EASL International Liver Congress 2021
-
-
-
-
-
-
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
15,929 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


